Results 141 to 150 of about 17,138 (209)

Head-to-head comparison of [¹⁷⁷Lu]Lu-FAP-2286 and [¹⁶¹Tb]Tb-FAP-2286 efficacy in a PDAC mouse model. [PDF]

EJNMMI Res
van der Heide CD, Ntihabose CM, Konijnenberg M, Ma H, Stuurman D, de Ridder C, Seimbille Y, Doukas MC, de Blois E, Dalm SU.   +9 more
europepmc   +1 more source

Linker Chemistry in Radiopharmaceutical Design. [PDF]

Bioconjug Chem
Stoddard A, Furey K, Dehlavi G, Mane MM, Sebastiano J, Zeglis BM.   +5 more
europepmc   +1 more source

Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer. [PDF]

Molecules
Sinha A, Pandya DN, Eeka P, Boyacioglu O, Gmeiner WH, Wadas TJ.   +5 more
europepmc   +1 more source

Radiopharmaceutical: An Update and Comparison of Preclinical Investigation Result of Alpha and Beta Emitter Radioisotope. [PDF]

Drug Des Devel Ther
Luhung A, Hasanah AN, Ramdhani D.
europepmc   +1 more source

Targeted β^--Particle Plus Conversion and Auger-Electron Therapy with ¹⁶¹Tb-Labeled Somatostatin Receptor Antagonist DOTA-LM3: A Phase 0 Study. [PDF]

J Nucl Med
Fricke JG, Westerbergh F, McDougall L, Favaretto C, Christ E, Nicolas GP, Geistlich S, Schmid DE, Borgna F, Fani M, Bernhardt P, van der Meulen NP, Müller C, Schibli R, Wild D.   +14 more
europepmc   +1 more source

A comparative assessment of radiochemical purity and yield of [¹⁸F]PSMA-1007 production using two different automated synthesis platforms: a head-to-head comparison. [PDF]

EJNMMI Radiopharm Chem
Cossandi M, Statuto M, Migliorati E, Viganò GL, Spiazzi L, Rodella C, Bellini P, Rinaldi R, Camoni L, Dondi F, Biasiotto G, Bertagna F.   +11 more
europepmc   +1 more source

Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid-β PET Drugs for Selection of Patients for Amyloid-β-Directed Therapies and Other Labeling Updates. [PDF]

J Nucl Med
Koo H, Mattay V, Hofling AA, Wang SJ, Krainak D, Kim Y, Krudys K, Buracchio T, Marzella L.   +8 more
europepmc   +1 more source

Correction to "Understanding time-activity curve and time-integrated activity variations in radiopharmaceutical therapy challenge: Experience and results". [PDF]

Med Phys
europepmc   +1 more source